90 related articles for article (PubMed ID: 15562384)
21. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
Damsbo P; Clauson P; Marbury TC; Windfeld K
Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
[TBL] [Abstract][Full Text] [Related]
22. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
[TBL] [Abstract][Full Text] [Related]
23. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan.
Sari R; Balci MK; Akbas SH; Avci B
Endocr Res; 2004 May; 30(2):169-77. PubMed ID: 15473127
[TBL] [Abstract][Full Text] [Related]
24. Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients.
Riccio A; Lisato G; de Kreutzenberg SV; Marchetto S; Turrin M; Tiengo A; Del Prato S
Metabolism; 1996 Oct; 45(10):1196-202. PubMed ID: 8843172
[TBL] [Abstract][Full Text] [Related]
25. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.
Wolffenbuttel BH; Nijst L; Sels JP; Menheere PP; Müller PG; Kruseman AC
Eur J Clin Pharmacol; 1993; 45(2):113-6. PubMed ID: 8223830
[TBL] [Abstract][Full Text] [Related]
26. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
[TBL] [Abstract][Full Text] [Related]
27. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
[TBL] [Abstract][Full Text] [Related]
28. Repaglinide--a new compound for the treatment of patients with type 2 diabetes.
Wolffenbuttel BH
Neth J Med; 1999 Nov; 55(5):229-34. PubMed ID: 10593133
[TBL] [Abstract][Full Text] [Related]
29. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
Goldberg RB; Einhorn D; Lucas CP; Rendell MS; Damsbo P; Huang WC; Strange P; Brodows RG
Diabetes Care; 1998 Nov; 21(11):1897-903. PubMed ID: 9802740
[TBL] [Abstract][Full Text] [Related]
30. Impact of the short-term, intense exercise on postprandial glycemia in type 2 diabetic patients treated with gliclazide.
Szewieczek J; Dulawa J; Strzałkowska D; Hornik B; Kawecki G
J Diabetes Complications; 2007; 21(2):101-7. PubMed ID: 17331858
[TBL] [Abstract][Full Text] [Related]
31. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Huang HK; Yeh JI
Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
[TBL] [Abstract][Full Text] [Related]
32. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients.
Tankova T; Koev D; Dakovska L; Kirilov G
Diabetes Res Clin Pract; 2003 Jan; 59(1):43-9. PubMed ID: 12482641
[TBL] [Abstract][Full Text] [Related]
33. Repaglinide.
Balfour JA; Faulds D
Drugs Aging; 1998 Aug; 13(2):173-80. PubMed ID: 9739505
[TBL] [Abstract][Full Text] [Related]
34. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
[TBL] [Abstract][Full Text] [Related]
35. Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.
Cozma LS; Luzio SD; Dunseath GJ; Underwood PM; Owens DR
Diabetes Care; 2005 May; 28(5):1001-7. PubMed ID: 15855557
[TBL] [Abstract][Full Text] [Related]
36. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes.
Moran A; Phillips J; Milla C
Diabetes Care; 2001 Oct; 24(10):1706-10. PubMed ID: 11574430
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia.
Dunning BE; Deacon R; Gutierrez C; Paladini S; Valentin MA; Foley JE
Diabetologia; 2003 Mar; 46 Suppl 1():M22-9. PubMed ID: 12652355
[TBL] [Abstract][Full Text] [Related]
38. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide.
Owens DR; Cozma LS; Luzio SD
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):19-27. PubMed ID: 12702004
[TBL] [Abstract][Full Text] [Related]
39. [Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2].
Rutten GE
Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1547-50. PubMed ID: 11525087
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.
Strange P; Schwartz SL; Graf RJ; Polvino W; Weston I; Marbury TC; Huang WC; Goldberg RB
Diabetes Technol Ther; 1999; 1(3):247-56. PubMed ID: 11475269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
